Certain human immunodeficiency virus (HIV)–infected patients, within 6 to 18 months of the initiation of antiretroviral therapy, develop fat redistribution abnormalities consisting of body peripheral fat wasting with central fat deposition.1,2 Treatment of these morphological abnormalities remains a difficult challenge for case management. However, there are few clinical data to support the ability of amprenavir (Agenerase) to cause less lipodystrophy. We describe a patient whose buffalo hump was reduced by changing his regimen from indinavir sulfate (Crixivan) to amprenavir.
Khanlou H, Adair M, Farthing C. Reduction of Buffalo Hump by Switching to Amprenavir in an HIV-Infected Patient. Arch Intern Med. 2000;160(22):3495–3496. doi: